Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in stage IVA nasopharyngeal cancer
NCT03734809Phase 2Active, not recruiting
- Sponsor
- The Chinese University of Hong Kong
- Start
- May 2019
- Primary completion
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of pembrolizumab in nasopharyngeal carcinoma (NPC), sponsored by The Chinese University of Hong Kong. Started May 2019; status: active, not recruiting.
02
Drugs
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03734809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03734809.